ID   UISO-RS-3
AC   CVCL_Y581
SY   University of Illinois Surgical Oncology-RhadbomyoSarcoma-3
DR   Wikidata; Q54990246
RX   PubMed=2243060;
RX   PubMed=23665679;
RX   PubMed=23882450;
CC   Doubling time: 1.5-2 days (Note=Depending on growth conditions) (PubMed=2243060).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3749; Alveolar rhabdomyosarcoma
DI   ORDO; Orphanet_99756; Alveolar rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   28Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 8
//
RX   PubMed=2243060; DOI=10.1007/BF02624471;
RA   Madsen W.E., Walker M.J., Shaughnessy E.A., Brown J.M.,
RA   Das Gupta T.K.;
RT   "Characterization of malignant mesenchymal cell line (UISO-RS-3)
RT   derived from a human rhabdomyosarcoma and inhibition by pharmacologic
RT   doses of estrogen.";
RL   In Vitro Cell. Dev. Biol. 26:971-977(1990).
//
RX   PubMed=23665679; DOI=10.1038/onc.2013.129;
RA   Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.;
RT   "Proof-of-concept rare cancers in drug development: the case for
RT   rhabdomyosarcoma.";
RL   Oncogene 33:1877-1889(2014).
//
RX   PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458;
RA   Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G.,
RA   Linardic C.M.;
RT   "Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research:
RT   utility and pitfalls.";
RL   Front. Oncol. 3:183.1-183.12(2013).
//